Knife River Corporation reported Q1 2026 results on May 5 that beat on both lines, yet the stock dropped 3.5% the next day — a setup where the numbers impressed but the market found reasons to pull back anyway.
The construction materials aggregates company posted Q1 EPS of -$1.40 against a -$1.43 estimate, with revenue of $410M clearing the $390M consensus by a comfortable margin. Q1 is seasonally weak for aggregates businesses, so the beat matters less for momentum than the guidance read-through: Knife River affirmed its full-year 2026 revenue range of $3.30–$3.50 billion. That midpoint sits just below the $3.41 billion analyst estimate, offering no upside surprise on forward numbers. The stock has rallied 18% over the past month, so a guidance reaffirmation rather than a raise was enough to dent sentiment after a sharp run-up.
Short positioning is moderate but ticking higher. SI reached 6.4% of free float on May 5, up just under 1% on the week and 4.5% over the past month. The borrow market reflects no real urgency: cost to borrow is running at about 0.5% — barely above benchmark — and has barely moved over the past six weeks despite the rising short count. Availability remains well above tight thresholds, meaning the lending pool is not under stress. The ORTEX short score of 51.7 sits in the middle of its range and has drifted only fractionally higher over the past fortnight. Days-to-cover of 6.5 days, per the FINRA fortnightly read, is elevated relative to the overall market but not alarming for a mid-cap construction name with seasonally lumpy volumes. The borrow dynamics tell a story of gradual short accumulation rather than a conviction-driven attack.
Options positioning has rotated sharply more bullish. The put/call ratio dropped to 0.59 — well below its 20-day average of 0.99 — with the z-score at -0.92. For comparison, in early-to-mid April, the PCR was running above 1.5; that hedging overhang has almost entirely unwound. Call buyers dominate the recent flow. The contrast with the short-side tick-up is notable: options traders have reduced downside protection at precisely the moment the stock faded on earnings day, suggesting the option book was positioned for a positive reaction that didn't fully materialise in price.
JP Morgan moved today, raising its price target to $95 from $90 while holding a Neutral rating. The timing — after the Q1 beat — is read as a modest sanity check rather than a conviction change. Wells Fargo retains an Underweight with a $80 target, trimmed very slightly to $80 from $81 in mid-April. The bull camp — DA Davidson at $105, Stephens & Co. at $105, RBC at $109 — argues the EDGE operational program drives Knife River toward a 20% EBITDA margin, with M&A optionality providing a growth runway. Bears, led by Wells Fargo, point to organic growth tracking around 9%, flat SG&A, and a guidance midpoint that offers no buffer against weather or project cancellations. The consensus is formally a Hold, with a mean price target around $105 — roughly 20% above Tuesday's close of $87.12. EV/EBITDA at around 10.7x has compressed by about half a turn over the past month as the stock ran. EPS momentum scores rank in the 76th percentile on a 30-day basis, reflecting the Q1 beat; earnings surprise ranks in the 68th percentile. Neither is exceptional, but both trend in the right direction.
On the institutional side, BlackRock holds the largest position at 12.4% of shares, with T. Rowe Price at 8.9% adding 212,000 shares in Q1. Neuberger Berman added over 400,000 shares in Q1, a meaningful addition for a firm that size. Insider activity is less encouraging: the most recent reported trades, all dated February 12, were clustered sell transactions spanning the CFO, Co-CEO, Chief Legal Officer, and President/CEO — several hundred thousand dollars each at $81.74. These may be plan-driven, but the coordinated timing is worth noting. With today's price at $87, those sellers netted less than a 7% upside from the sale price, while the stock has since rallied further on the Q1 beat. There are no buys on record in the recent window.
With a Q2 earnings event flagged for May 20, the next read will determine whether the revenue beat is a genuine inflection in spring construction demand or a function of easy comparables. The more interesting question is whether the PCR de-risking proves premature given the flat post-results price action.
See the live data behind this article on ORTEX.
Open KNF on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
